Nature Reviews Drug Discovery
@natrevdrugdiscov.nature.com
Editorial team of Nature Reviews Drug Discovery
www.nature.com/nrd
www.nature.com/nrd
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41...
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
November 5, 2025 at 3:35 PM
FDA approves PDE4 inhibitor for idiopathic pulmonary fibrosis www.nature.com/articles/d41...
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
Boehringer Ingelheim's nerandomilast is the first new drug to be approved for this fatal lung disease in more than a decade
For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review
rdcu.be/eN4SK
www.nature.com/articles/s41...
rdcu.be/eN4SK
www.nature.com/articles/s41...
November 3, 2025 at 4:31 PM
For readers interested in new drugs for chronic obstructive pulmonary disease, affecting proteins such as IL-33 and TSLP that are targeted by the bispecific involved in Roche's $1 billion deal with Qyuns Therapeutics, here's a review
rdcu.be/eN4SK
www.nature.com/articles/s41...
rdcu.be/eN4SK
www.nature.com/articles/s41...
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...
October 30, 2025 at 2:42 PM
Our November issue is live! Read more about drugs for cancer cachexia, RNA chemistry and therapeutics, targeting the Hippo pathway in cancer, the changing landscape of medicinal chemistry optimization and more here www.nature.com/nrd/volumes/...
Innovation in medicines for global health: a 20-year landscape analysis
nature.com/articles/d41...
This article analyses progress in the development of drugs for diseases including Ebola, trypanosomiasis, malaria, onchocerciasis, sickle cell disease, thalassaemia and tuberculosis
nature.com/articles/d41...
This article analyses progress in the development of drugs for diseases including Ebola, trypanosomiasis, malaria, onchocerciasis, sickle cell disease, thalassaemia and tuberculosis
October 14, 2025 at 2:39 PM
Innovation in medicines for global health: a 20-year landscape analysis
nature.com/articles/d41...
This article analyses progress in the development of drugs for diseases including Ebola, trypanosomiasis, malaria, onchocerciasis, sickle cell disease, thalassaemia and tuberculosis
nature.com/articles/d41...
This article analyses progress in the development of drugs for diseases including Ebola, trypanosomiasis, malaria, onchocerciasis, sickle cell disease, thalassaemia and tuberculosis
Cancer cachexia contender enters first pivotal trial www.nature.com/articles/d41...
Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges
Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges
October 10, 2025 at 2:22 PM
Cancer cachexia contender enters first pivotal trial www.nature.com/articles/d41...
Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges
Can Pfizer’s appetite-boosting antibody ponsegromab address a cancer-induced wasting syndrome — and help patients live longer in the process? Find out more in this news article #CancerGrandChallenges
Novo Nordisk's $4.7 billion upfront purchase of Akero to gain its FGF21 analogue for MASH today follows Roche's potential $3.5 billion deal around a similar drug from 89bio last month www.nature.com/articles/d41...
Read more about FGF21 analogues in this review rdcu.be/eKbyo
Read more about FGF21 analogues in this review rdcu.be/eKbyo
October 9, 2025 at 2:01 PM
Novo Nordisk's $4.7 billion upfront purchase of Akero to gain its FGF21 analogue for MASH today follows Roche's potential $3.5 billion deal around a similar drug from 89bio last month www.nature.com/articles/d41...
Read more about FGF21 analogues in this review rdcu.be/eKbyo
Read more about FGF21 analogues in this review rdcu.be/eKbyo
Genmab nabs EGFR × LGR5 bispecific in US$8 billion Merus acquisition www.nature.com/articles/d41...
For readers interested in bispecific antibodies in oncology, here's a comprehensive review rdcu.be/eJ2XM
www.nature.com/articles/s41...
For readers interested in bispecific antibodies in oncology, here's a comprehensive review rdcu.be/eJ2XM
www.nature.com/articles/s41...
October 8, 2025 at 2:49 PM
Genmab nabs EGFR × LGR5 bispecific in US$8 billion Merus acquisition www.nature.com/articles/d41...
For readers interested in bispecific antibodies in oncology, here's a comprehensive review rdcu.be/eJ2XM
www.nature.com/articles/s41...
For readers interested in bispecific antibodies in oncology, here's a comprehensive review rdcu.be/eJ2XM
www.nature.com/articles/s41...
Today's Nobel Prize for Physiology or Medicine relates to research on regulatory T cells www.nobelprize.org/prizes/medic...
For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/eJHU8
For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/eJHU8
October 6, 2025 at 2:40 PM
Today's Nobel Prize for Physiology or Medicine relates to research on regulatory T cells www.nobelprize.org/prizes/medic...
For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/eJHU8
For readers interested in harnessing the biology of regulatory T cells to treat disease, here's a comprehensive review www.nature.com/articles/s41...
rdcu.be/eJHU8
Our October issue is live! Read more about targeting protein disorder in drug discovery, metabolites as agents and targets for cancer immunotherapy, targeting DNA damage in ageing and more here www.nature.com/nrd/volumes/...
October 3, 2025 at 2:17 PM
Our October issue is live! Read more about targeting protein disorder in drug discovery, metabolites as agents and targets for cancer immunotherapy, targeting DNA damage in ageing and more here www.nature.com/nrd/volumes/...
In vivo CAR-T cell therapy
www.nature.com/articles/s41...
rdcu.be/eI7zH
This new Review discusses how technological advances that remove the need for ex vivo manipulation and chemotherapeutic conditioning could enable wider application of CAR-T cell therapies in blood cancers and autoimmune diseases
www.nature.com/articles/s41...
rdcu.be/eI7zH
This new Review discusses how technological advances that remove the need for ex vivo manipulation and chemotherapeutic conditioning could enable wider application of CAR-T cell therapies in blood cancers and autoimmune diseases
October 2, 2025 at 2:15 PM
In vivo CAR-T cell therapy
www.nature.com/articles/s41...
rdcu.be/eI7zH
This new Review discusses how technological advances that remove the need for ex vivo manipulation and chemotherapeutic conditioning could enable wider application of CAR-T cell therapies in blood cancers and autoimmune diseases
www.nature.com/articles/s41...
rdcu.be/eI7zH
This new Review discusses how technological advances that remove the need for ex vivo manipulation and chemotherapeutic conditioning could enable wider application of CAR-T cell therapies in blood cancers and autoimmune diseases
This new article analyses the evolution of the pipeline and market for obesity drugs, which is being transformed by GLP-1-based therapies www.nature.com/articles/d41...
September 24, 2025 at 1:33 PM
This new article analyses the evolution of the pipeline and market for obesity drugs, which is being transformed by GLP-1-based therapies www.nature.com/articles/d41...
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
www.nature.com/articles/s41...
rdcu.be/eHOJ9
This new Review discusses progress with drugs targeting inflammatory cytokines such as IL-4 and IL-5, neutrophils, alarmins and kinases
www.nature.com/articles/s41...
rdcu.be/eHOJ9
This new Review discusses progress with drugs targeting inflammatory cytokines such as IL-4 and IL-5, neutrophils, alarmins and kinases
September 23, 2025 at 2:54 PM
Treatment of chronic obstructive pulmonary disease: current pipeline and new opportunities
www.nature.com/articles/s41...
rdcu.be/eHOJ9
This new Review discusses progress with drugs targeting inflammatory cytokines such as IL-4 and IL-5, neutrophils, alarmins and kinases
www.nature.com/articles/s41...
rdcu.be/eHOJ9
This new Review discusses progress with drugs targeting inflammatory cytokines such as IL-4 and IL-5, neutrophils, alarmins and kinases
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning
www.nature.com/articles/d41...
www.nature.com/articles/d41...
September 11, 2025 at 2:46 PM
Novel drug candidates for hard-to-treat hypertension vie for blockbuster positioning
www.nature.com/articles/d41...
www.nature.com/articles/d41...
New online: Synthetic lethality in cancer drug discovery: challenges and opportunities
www.nature.com/articles/s41...
rdcu.be/eFDCl
This Review discusses advances in the discovery and validation of synthetic lethal pairs, and the development of drugs that target them
www.nature.com/articles/s41...
rdcu.be/eFDCl
This Review discusses advances in the discovery and validation of synthetic lethal pairs, and the development of drugs that target them
September 11, 2025 at 2:37 PM
New online: Synthetic lethality in cancer drug discovery: challenges and opportunities
www.nature.com/articles/s41...
rdcu.be/eFDCl
This Review discusses advances in the discovery and validation of synthetic lethal pairs, and the development of drugs that target them
www.nature.com/articles/s41...
rdcu.be/eFDCl
This Review discusses advances in the discovery and validation of synthetic lethal pairs, and the development of drugs that target them
Chemical modification and engineering approaches for guide RNAs can enhance or enable CRISPR-based therapies by addressing issues such as delivery, stability, editing efficiency and off-target effects - find out more in this review www.nature.com/articles/s41...
rdcu.be/eFb79
rdcu.be/eFb79
September 9, 2025 at 2:08 PM
Chemical modification and engineering approaches for guide RNAs can enhance or enable CRISPR-based therapies by addressing issues such as delivery, stability, editing efficiency and off-target effects - find out more in this review www.nature.com/articles/s41...
rdcu.be/eFb79
rdcu.be/eFb79
For readers interested in cancer therapies, this Review in our September issue discusses molecular pathways and effector functions by which neutrophils modulate cancer progression, and considers tractable therapeutic targets
www.nature.com/articles/s41...
rdcu.be/eEVmh
www.nature.com/articles/s41...
rdcu.be/eEVmh
September 8, 2025 at 2:15 PM
For readers interested in cancer therapies, this Review in our September issue discusses molecular pathways and effector functions by which neutrophils modulate cancer progression, and considers tractable therapeutic targets
www.nature.com/articles/s41...
rdcu.be/eEVmh
www.nature.com/articles/s41...
rdcu.be/eEVmh
The gut microbiome has a key role in shaping the immune response to cancer and influencing the efficacy of immunotherapy. Read about advances in targeting the microbiome in cancer treatment in this Review in the September issue
www.nature.com/articles/s41...
rdcu.be/eD8M5
www.nature.com/articles/s41...
rdcu.be/eD8M5
September 4, 2025 at 2:02 PM
The gut microbiome has a key role in shaping the immune response to cancer and influencing the efficacy of immunotherapy. Read about advances in targeting the microbiome in cancer treatment in this Review in the September issue
www.nature.com/articles/s41...
rdcu.be/eD8M5
www.nature.com/articles/s41...
rdcu.be/eD8M5
New approach methodologies offer the promise of greater predictivity of safety risks of drug candidates than animal models. Find out about progress in their application in drug development in this article in the September issue
www.nature.com/articles/s41...
rdcu.be/eDV1s
www.nature.com/articles/s41...
rdcu.be/eDV1s
September 3, 2025 at 2:31 PM
New approach methodologies offer the promise of greater predictivity of safety risks of drug candidates than animal models. Find out about progress in their application in drug development in this article in the September issue
www.nature.com/articles/s41...
rdcu.be/eDV1s
www.nature.com/articles/s41...
rdcu.be/eDV1s
Our September issue is live! Read about targeting neutrophils for cancer therapy, application of new approach methodologies in safety assessment, the gut microbiome and cancer immunotherapy, and more here www.nature.com/nrd/volumes/...
September 2, 2025 at 2:40 PM
Our September issue is live! Read about targeting neutrophils for cancer therapy, application of new approach methodologies in safety assessment, the gut microbiome and cancer immunotherapy, and more here www.nature.com/nrd/volumes/...
From gene hunter to drug hunter
www.nature.com/articles/d41...
Howard Chang, Amgen’s new CSO, discusses genetic target discovery, extrachromosomal DNA and technology development
www.nature.com/articles/d41...
Howard Chang, Amgen’s new CSO, discusses genetic target discovery, extrachromosomal DNA and technology development
August 14, 2025 at 2:51 PM
From gene hunter to drug hunter
www.nature.com/articles/d41...
Howard Chang, Amgen’s new CSO, discusses genetic target discovery, extrachromosomal DNA and technology development
www.nature.com/articles/d41...
Howard Chang, Amgen’s new CSO, discusses genetic target discovery, extrachromosomal DNA and technology development
Neutrophil-targeted drug brensocatib secures first FDA approval for inflammatory lung disease nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
August 12, 2025 at 4:54 PM
Neutrophil-targeted drug brensocatib secures first FDA approval for inflammatory lung disease nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
The first-in-class DPP1 inhibitor is anticipated to have annual sales of >US$4 billion. Read more about the DPP1 inhibitor pipeline here nature.com/articles/d41...
Dual-payload antibody-drug conjugates move into first oncology clinical trials nature.com/articles/d41...
Find out why a rapidly growing number of companies are betting that two different warheads on ADCs for cancer could be better than one in this news story in the August issue
Find out why a rapidly growing number of companies are betting that two different warheads on ADCs for cancer could be better than one in this news story in the August issue
August 6, 2025 at 3:19 PM
Dual-payload antibody-drug conjugates move into first oncology clinical trials nature.com/articles/d41...
Find out why a rapidly growing number of companies are betting that two different warheads on ADCs for cancer could be better than one in this news story in the August issue
Find out why a rapidly growing number of companies are betting that two different warheads on ADCs for cancer could be better than one in this news story in the August issue
Our latest research highlight covers a paper in Science on an in vivo CAR-T cell therapy platform based on mRNA-loaded lipid nanoparticles nature.com/articles/d41...
AbbVie recently paid $2.1 billion to buy the company that developed the platform, Capstan Therapeutics nature.com/articles/d41...
AbbVie recently paid $2.1 billion to buy the company that developed the platform, Capstan Therapeutics nature.com/articles/d41...
August 5, 2025 at 3:20 PM
Our latest research highlight covers a paper in Science on an in vivo CAR-T cell therapy platform based on mRNA-loaded lipid nanoparticles nature.com/articles/d41...
AbbVie recently paid $2.1 billion to buy the company that developed the platform, Capstan Therapeutics nature.com/articles/d41...
AbbVie recently paid $2.1 billion to buy the company that developed the platform, Capstan Therapeutics nature.com/articles/d41...
Our August issue is live! Read about antibody-drug conjugates with dual payloads, GLP-1-based therapies, biomarker-guided drug development for neurodegenerative disorders, immunomodulators targeting the aryl hydrocarbon receptor and more here www.nature.com/nrd/volumes/...
August 4, 2025 at 2:21 PM
Our August issue is live! Read about antibody-drug conjugates with dual payloads, GLP-1-based therapies, biomarker-guided drug development for neurodegenerative disorders, immunomodulators targeting the aryl hydrocarbon receptor and more here www.nature.com/nrd/volumes/...
Trends in the development of cellular and gene therapy in China www.nature.com/articles/d41...
This new article analyses the landscape for cell and gene therapy in China, including the characteristics of products in clinical trials and those that have been approved
This new article analyses the landscape for cell and gene therapy in China, including the characteristics of products in clinical trials and those that have been approved
July 31, 2025 at 2:40 PM
Trends in the development of cellular and gene therapy in China www.nature.com/articles/d41...
This new article analyses the landscape for cell and gene therapy in China, including the characteristics of products in clinical trials and those that have been approved
This new article analyses the landscape for cell and gene therapy in China, including the characteristics of products in clinical trials and those that have been approved